News Releases


BioSante Pharmaceuticals, Inc. To Present At OneMedForum and Biotech Showcase Conferences

LINCOLNSHIRE, Illinois (January 6, 2010) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the OneMedForum and Biotech Showcase Conferences in San Francisco.

Stephen M. Simes, BioSante’s president & CEO, will present at the OneMedForum on Tuesday January 12, 2010 at 11:30 am PST and Phillip B. Donenberg, BioSante’s CFO will present at the Biotech Showcase on the same day at 2:40 pm PST. BioSante will present an overview of the company and its recently completed acquisition of Cell Genesys, as well as a LibiGel® (testosterone gel) update. A live audio webcast of the OneMedForum presentation may be accessed at and a replay will be available at the same link.

Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. The Biotech Showcase is focused on biotechnology and provides presenting companies an opportunity to present to an audience of investors and biopharmaceutical business development executives.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology.

The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, 2A/Furin and other technologies. Additional information is available online at:


For more information please contact:

For Media:
Harris D. McKinney, Inc.
Alan Zachary
(312) 506-5220